Intranasal Inactivated Sarbecovirus Vaccine With TLR7/8 Agonist Adjuvant Elicits Cross-Reactive Mucosal and Systemic Immunity Against SARS-CoV-2 Variants and Pre-Emergent Bat Coronaviruses
This study investigates intranasal inactivated pan-sarbecovirus vaccine adjuvanted with TLR7/8 agonist inducing cross-reactive mucosal IgA, neutralizing antibodies, and T cell responses against SARS-CoV-2 variants and bat sarbecoviruses in macaque and hamster models within the context of vaccine immunology and pandemic...